How i treat... dyslipidaemia according to the cardiovascular risk profile;Comment je traite... une dyslipidémie en fonction du profil de risque cardiovasculaire

Revue Medicale de Liege

Volumn 67, Issue 4, 2012, Pages 167-173

  Descamps, O S ^a   Scheen, A J ^b   De Backer, G ^c,f   Annemans, L ^d   Muls, E ^e   Carpentier, Y ^f   Descamps, O ^f   Ducobu, J ^f   Herman, A ^f   Langlois, M ^f   Radermecker, R ^f   Rietzschel, E ^f  

^a Hospital de Jolimont   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d GHENT UNIVERSITY   (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f NONE

Author keywords

Cardiovascular disease; Cardiovascular risk; Cholesterol; Diabetes; Prevention; Therapeutic target; Triglycerides

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BELGIUM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DYSLIPIDEMIA; FOLLOW UP; HUMAN; LIPID ANALYSIS; MEDICAL PRACTICE; MEDICAL SOCIETY; PRIMARY PREVENTION; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT;

EID: 84860858207     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (10)

1. Reiner Z, Catapano AL, De Backer G, et al. - ESC/EAS Guidelines for the management of dyslipidaemias : the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Association for Cardiovascular Prevention & Rehabilitation. Eur Heart J, 2011, 32, 1769-1818.
2. Descamps OS, De Backer G, Muls E, Scheen AJ, Belgian Atherosclerosis Society/ Belgian Lipid Club. - Les nouvelles recommandations européennes pour le traitement des dyslipidémies en prévention cardiovasculaire. Rev Med Liège, 2012, 67.
3. INAMI. - Usage et prescription des statines 2010. http://www.inami.be/ drug/fr/drugs/recommendation/pdf/table-statines.pdf
4. Descamps O, Cooney MT, Graham I, De Backer G. - A simple multiplier to calculate the impact of HDL cholesterol on cardiovascular risk estimation using SCORE. Atherosclerosis, 2012, Submitted.
5. Descamps OS, Tenoutasse S, Stephenne X, et al. - Management of familial hypercholesterolemia in children and young adults : consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis, 2011, 218, 272-280.
6. Paquot N, Scheen AJ. - Quelles cibles glycémiques et lipidiques viser chez un patient diabétique de type 2 ? Rev Med Liège, 2012, 67, 98-103.
7. Scheen AJ, Kulbertus H. - Prévention cardiovasculaire par les statines : faut-il encore doser le cholesterol ? Rev Med Liège, 2003, 58, 191-197. (Pubitemid 37013903)
8. Ducobu J, Scheen A, Van Gaal L, et al. - Belgian expert opinion : how to reduce the residual risk in atherogenic-dyslipidaemic patients : place of fibrates. Acta Cardiol, 2008, 63, 235-248. (Pubitemid 351548712)
9. Scheen AJ, Radermecker RP. - Ezétimibe (Ezetrol®) chez le patient diabétique. Rev Med Liège, 2009, 64, 606-611.
10. Radermecker RP, Scheen AJ. - Comment optimaliser le traitement hypolipidémiant : ne pas oublier la problématique du défaut d'observance. Rev Med Liège, 2010, 65, 311-317.